Abalone Bio, Inc.

Therapeutic Antibodies for Treating Chemotherapy Induced Peripheral Neuropathic Pain - Abstract Chemotherapy-induced Peripheral Neuropathy (CIPN) Is an Often Long-lasting Neurological Condition That Arises Frequently in Cancer Patients Who Receive Broadly Used Chemotherapies Such as Taxanes. Cipn Causes Abnormal Pain and Other Symptoms That Can Limit Chemotherapy Dosage and Significantly Impact Quality of Life for Years. There Are No Drugs That Prevent Cipn or Treat It Well. Duloxetine Is the Only Clinically Proven Efficacious Pain- Reducing Agent, Though It Can Cause Significant Side Effects and Its Efficacy Limited to a Subset of Patients. Opioids Are Used Off-label, But Also Carry Serious Side Effects. Thus, There Is a Critical Unmet Need for Drugs That Safely and Effectively Treat or Prevent Cipn. Peripheral Cannabinoid 2 Receptors (CB2) Are a Promising Target for Cipn Treatment. CB2 Is Constitutively Expressed on Inflammatory Immune Cells and Induced in Peripheral Neurons in Neuropathic Conditions. Its Activation Has Powerful Neuroprotective, Anti-inflammatory, and Analgesic Effects. Rodent Models of Cipn Show That Small Molecule CB2 Agonists Alleviate Neuropathic Pain Behavior, and When Administered Prophylactically Suppress Cipn Both During Dosing and for 100 Days After. Several Companies Have Developed Small Molecule CB2 Agonists That, Unfortunately, Are Rapidly Cleared, Penetrate the Blood-brain Barrier And/or Have Off-target Effects (notably Cognitive Ones) Mediated by the CB1 Receptor. Abalone Bio Used Its Proprietary Functional Antibody Selection Technology (FAST) to Isolate a Selective CB2-ACTIVATING Nanobody (VHH), Which We Converted Into a Vhh-fc Fusion Lead Antibody, ABT140, for in Vivo Studies. Phase I Sbir Results Show That ABT140 Rapidly and Durably Reversed Allodynia in Mice With Cipn. in This Phase Ii Sbir Project, Abalone Bio Will First Improve ABT140’S Immunogenicity and Manufacturability by Rational Engineering, and Then the Fast Platform Will Be Used to Increase Its Potency to Select Durable Agonists From Millions of Computationally- Designed Variants. We Will Select 1 Lead and at Least 2 Alternates Using in Vitro and in Vivo Assays. Using the Paclitaxel Cipn Mouse Model, We Will Assess the Lead’s Ability to Prevent Cipn Development, Reduce in Nerve Damage and Inflammation, Show No Impairment of Motor Skills, and Not Affect Chemotherapy’s Anti-tumor Efficacy. Finally, We Will Determine the Lead Antibody’s Half-life and Tissue Distribution in Mice, and Using Blood Markers and Organs Appearance and Weight, We Will Assess Its Toxicity at High Doses. Successful Completion of These Aims Will De-risk the Project Sufficiently to Advance Abalone’s Antibody Drug to Ind-enabling Studies and Eventually First in Human Trials for Painful Cipn. Abalone’s Drug May Also Have Broad Utility for Other Neuropathic Pains and Inflammatory Conditions.